Hyppää sisältöön
    • FI
    • ENG
  • FI
  • /
  • EN
OuluREPO – Oulun yliopiston julkaisuarkisto / University of Oulu repository
Näytä viite 
  •   OuluREPO etusivu
  • Oulun yliopisto
  • Avoin saatavuus
  • Näytä viite
  •   OuluREPO etusivu
  • Oulun yliopisto
  • Avoin saatavuus
  • Näytä viite
JavaScript is disabled for your browser. Some features of this site may not work without it.

Optimal timing for cardioversion in patients with atrial fibrillation

Hellman, Tapio; Kiviniemi, Tuomas; Nuotio, Ilpo; Biancari, Fausto; Vasankari, Tuija; Hartikainen, Juha; Lehto, Mika; Airaksinen, K.E. (2018-05-26)

 
Avaa tiedosto
nbnfi-fe2018103039063.pdf (1.996Mt)
nbnfi-fe2018103039063_meta.xml (42.18Kt)
nbnfi-fe2018103039063_solr.xml (45.23Kt)
Lataukset: 

URL:
https://doi.org/10.1002/clc.22986

Hellman, Tapio
Kiviniemi, Tuomas
Nuotio, Ilpo
Biancari, Fausto
Vasankari, Tuija
Hartikainen, Juha
Lehto, Mika
Airaksinen, K.E.
John Wiley & Sons
26.05.2018

Hellman T, Kiviniemi T, Nuotio I, et al. Optimal timing for cardioversion in patients with atrial fibrillation. Clin Cardiol. 2018;41:966–971. https://doi.org/10.1002/clc.22986

https://rightsstatements.org/vocab/InC/1.0/
© 2018 Wiley Periodicals, Inc. This is the peer reviewed version of the following article: Hellman T, Kiviniemi T, Nuotio I, et al. Optimal timing for cardioversion in patients with atrial fibrillation. Clin Cardiol. 2018;41:966–971. https://doi.org/10.1002/clc.22986, which has been published in final form at https://doi.org/10.1002/clc.22986. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
https://rightsstatements.org/vocab/InC/1.0/
doi:https://doi.org/10.1002/clc.22986
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi-fe2018103039063
Tiivistelmä

Abstract

Background: Electrical cardioversion (CV) is essential in rhythm management of atrial fibrillation (AF). However, optimal timing of CV remains unknown.

Hypothesis: Timing of CV in AF is associated with risk of adverse events.

Methods: We analyzed the effect of AF episode duration on safety and efficacy of electrical CV in a multicenter, multicohort study exploring 4356 CVs in 2530 patients on oral anticoagulation. The composite adverse outcome included unsuccessful CV, acute arrhythmic complications, thromboembolic events, mortality, and AF recurrence within 30‐day follow‐up.

Results: Study groups were stratified according to duration of index AF episode (<24 h, 24–48 h, 48 h–30d, and > 30d), consisting of 1767, 516, 632, and 1441 CVs, respectively. CVs were unsuccessful in 8.5% (<24 h), 5.4% (24–48 h), 11.1% (48 h–30d), and 13.9% (>30d), respectively (P < 0.01). Occurrence of thromboembolic events (0.1%), mortality (0.1%), and asystole >5 seconds (0.7%) within 30‐day follow‐up was infrequent and comparable in the study groups. AF recurrence within 30 days after initially successful CVs was 29.8% (<24 h), 26.5% (24–48 h), 37.3% (48 h–30d), and 30.3% (>30d), respectively (P < 0.01). Composite adverse outcome occurred in 1669 (38.4%) CVs, and index AF episode >48 hours was an independent predictor for the composite endpoint (OR: 1.49, 95% CI: 1.28–1.74, P < 0.01) in multivariate analysis.

Conclusions: Optimal timing of CV for AF showed a J‐shaped curve, with fewest adverse outcomes in patients with CV performed 24 to 48 hours after onset of AF. In patients with rhythm‐control strategy, delaying CV >48 hours is associated with increased risk for adverse outcomes.

Kokoelmat
  • Avoin saatavuus [38670]
oulurepo@oulu.fiOulun yliopiston kirjastoOuluCRISLaturiMuuntaja
SaavutettavuusselosteTietosuojailmoitusYlläpidon kirjautuminen
 

Selaa kokoelmaa

NimekkeetTekijätJulkaisuajatAsiasanatUusimmatSivukartta

Omat tiedot

Kirjaudu sisäänRekisteröidy
oulurepo@oulu.fiOulun yliopiston kirjastoOuluCRISLaturiMuuntaja
SaavutettavuusselosteTietosuojailmoitusYlläpidon kirjautuminen